114.12
전일 마감가:
$114.80
열려 있는:
$113.45
하루 거래량:
1.51M
Relative Volume:
1.92
시가총액:
$6.41B
수익:
$633.51M
순이익/손실:
$-8.10M
주가수익비율:
-368.13
EPS:
-0.31
순현금흐름:
$131.26M
1주 성능:
-3.37%
1개월 성능:
-3.98%
6개월 성능:
-31.60%
1년 성능:
-11.93%
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
RGEN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RGEN
Repligen Corp
|
114.12 | 6.64B | 633.51M | -8.10M | 131.26M | -0.31 |
![]()
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-22 | 재개 | Stephens | Overweight |
2025-06-24 | 개시 | Barclays | Overweight |
2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
2025-03-18 | 개시 | Evercore ISI | In-line |
2025-02-10 | 개시 | TD Cowen | Buy |
2024-12-17 | 개시 | Canaccord Genuity | Hold |
2024-11-14 | 개시 | Wolfe Research | Peer Perform |
2024-08-28 | 개시 | Wells Fargo | Overweight |
2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
2024-06-18 | 개시 | Guggenheim | Neutral |
2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2023-07-20 | 개시 | Wells Fargo | Overweight |
2023-07-05 | 재개 | JP Morgan | Overweight |
2023-03-28 | 개시 | The Benchmark Company | Buy |
2022-12-14 | 개시 | Deutsche Bank | Hold |
2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
2022-07-20 | 개시 | UBS | Buy |
2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
2020-08-24 | 재확인 | H.C. Wainwright | Buy |
2020-06-30 | 재확인 | H.C. Wainwright | Buy |
2020-05-07 | 재확인 | H.C. Wainwright | Buy |
2020-03-23 | 재확인 | H.C. Wainwright | Buy |
2019-11-15 | 개시 | Stifel | Buy |
2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
2019-10-15 | 개시 | SVB Leerink | Outperform |
2019-08-28 | 재확인 | First Analysis Sec | Outperform |
2019-08-23 | 재개 | Stephens | Overweight |
2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
2018-09-26 | 개시 | H.C. Wainwright | Neutral |
2017-12-08 | 개시 | Citigroup | Buy |
2017-12-05 | 개시 | JP Morgan | Overweight |
2017-11-13 | 개시 | CL King | Buy |
2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
2017-07-21 | 개시 | William Blair | Outperform |
2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Repligen (RGEN) Receives Overweight Rating with $160 Price Targe - GuruFocus
Here's Why Repligen (RGEN) is a Strong Growth Stock - Yahoo Finance
Repligen FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
What analysts say about Repligen Corporation stockExplosive portfolio gains - printweek.in
Envestnet Asset Management Inc. Reduces Position in Repligen Corporation (NASDAQ:RGEN) - Defense World
Repligen Corp to Release Q2 2025 Financial Results and Host Conference Call on July 29, 2025. - AInvest
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know - Yahoo Finance
M&T Bank Corp Reduces Stake in Repligen Corporation (NASDAQ:RGEN) - Defense World
Repligen to Report Second Quarter 2025 Financial Results - The Globe and Mail
Repligen Corporation to Announce Second Quarter 2025 Financial Results on July 29 - Quiver Quantitative
How KEY.PRK stock performs during market volatilityFree Consultation - Newser
Why DOCU stock attracts strong analyst attentionHigh Potential Shares - Newser
How Life360 Inc. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser
Protein Purification and Isolation Market Size to Surpass USD 33.02 Billion by 2034 - BioSpace
Parnassus Mid Cap Growth Fund Q2 2025 Commentary - Seeking Alpha
Parnassus Mid Cap Fund Q2 2025 Commentary - Seeking Alpha
Why Repligen Corporation stock attracts strong analyst attentionInstant Stock Updates - Newser
What makes ScanSource Inc. stock price move sharplyFree Stock Market Forecasting Tools - Newser
What makes HUTCHMED (China) Limited Depositary Receipt stock price move sharplyFree Join Group - Newser
How Repligen Corporation stock performs during market volatility200 Percent Profit Outlook - Newser
Why Sphere 3D Corp. stock attracts strong analyst attentionFree Stock Trading Community - Newser
Why ROAD stock attracts strong analyst attentionTop Analyst Picks - Newser
Evercore ISI Cuts Repligen (NASDAQ:RGEN) Price Target to $130.00 - Defense World
Repligen And 2 Other Stocks That May Be Trading Below Estimated Value - Yahoo Finance
GAMMA Investing LLC Boosts Holdings in Repligen Corporation (NASDAQ:RGEN) - Defense World
Repligen Corporation (NASDAQ:RGEN) Shares Purchased by KBC Group NV - Defense World
Fluor Corporation (NYSE:FLR) Shares Sold by Amalgamated Bank - Defense World
Wall Street Zen Downgrades Repligen (NASDAQ:RGEN) to Hold - Defense World
Improving Process Reliability in mAb Manufacturing - Genetic Engineering and Biotechnology News
Barclays Initiates Coverage on Repligen (RGEN) with Positive Out - GuruFocus
Barclays initiates Repligen stock with overweight rating on bioprocessing strength - Investing.com
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Yousif Capital Management LLC Has $2.01 Million Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Does Repligen Corp (RGEN) Have a Strong Pricing Power? - Insider Monkey
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Parallel Advisors LLC Has $36,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Three Stocks That May Be Trading Below Their Intrinsic Value In June 2025 - Yahoo Finance
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen at William Blair Conference: Innovation Drives Growth By Investing.com - Investing.com Canada
Repligen at William Blair Conference: Innovation Drives Growth - Investing.com
Repligen Corp (RGEN) Stock Price Up 5% on Jun 3 - GuruFocus
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers - Yahoo Finance
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? - Yahoo Finance
Repligen Corp (RGEN) Trading Down 3.33% on May 30 - GuruFocus
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? - Yahoo Finance
Cetera Investment Advisers Has $436,000 Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp (RGEN) Stock Price Up 4.35% on May 27 - GuruFocus
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report - The Manila Times
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report - TradingView
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth challenges By Investing.com - Investing.com UK
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):